CompletedPhase 4

Using Flavonoids to Kill Hepatitis B Virus

United States, Vietnam134 participantsStarted 2015-11-30

Plain-language summary

The composition treats Acute Hepatitis, Chronic Hepatitis, Cirrhosis, and hepatocellular carcinoma (S.B.Flavonoids) at an early stage. The product is ascorbic acid, L-Arginine hydrochloride, Kaempferol, Urinariaflavone, 5,6-dihydroxy-7,8,4'-trimethoxy-flavone, Quercetin, and Rutin. These components have participated in protecting liver cell membranes, focusing on reducing liver stress and supporting their structure, repairing and regenerating new liver parenchyma, preventing fibrosis cell generation, and preventing liver cancer cell growth at an early stage. The composition supplements precursors that help the body strengthen antibodies and reduce the risk of inflammation, and restore the physiological and biochemical functions of liver cells after chronic inflammation.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients with underlying medical conditions who have been taking medications for these conditions. * Patients with AIDS, HIV, HBV, HCV, and patients with co-infections. * The cancer patients are stable. * Patients with congenital or acquired immunodeficiency. Exclusion Criteria: * Unstable cancer patients. * Decompensated cirrhosis.

What they're measuring

Quantification of HBV-DNA, SGPT, SGOT. The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis

Timeframe: 36 months

Trial details

NCT IDNCT07084948

SponsorTrieu, Nguyen Thi, M.D.

Sponsor typeINDIV

Study typeINTERVENTIONAL

Primary completion2021-10-10

View on ClinicalTrials.gov More Hepatitis B Virus Infection trials